Drugs / Cerebiome
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05646784 | Jan 2024 → Jan 2025 | mood disorder | St Joseph University, Beirut, Lebanon | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-30 | Lallemand Pharma AG | Introducing CEREBIOME®: Pioneering psychobiotic: Game-changing science lallemand.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEREBIOME | “Specific objective: The evaluation of probiotic intake (CEREBIOME®, Lallemand Health Solutions Inc., Mirabel, Canada) on the inflammatory state, gut bacterial profile and the...” NCT05646784 ↗ |
| Modality | Other / unclassified | “oral intake of a probiotic agent” NCT05646784 ↗ |
| Route | Oral | “oral intake of a probiotic agent” NCT05646784 ↗ |